Urogynaecological Symptoms among Oncological Survivors and Impact of Oncological Treatment on Pelvic Floor Disorders and Lower Urinary Tract Symptoms. A Six-Month Follow-Up Study

Ziętek-Strobl, Alicja; Futyma, Konrad; Kuna-Broniowska, Izabela; Wojtaś, Małgorzata; Rechberger, Tomasz

doi:10.3390/jcm9092804

Cited by 11 publications

(13 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Following an examination of the titles and abstracts, 51 publications were retrieved in their entirety , with 10 eventually qualifying for this study (Fig. 1) [13][14][15][16][17][18][19][20][21][22]. Most of the studies were retrospective cross-sectional, with the evaluation of PFD taking place at some point following the EC therapy; only 3 of them were prospective, and the overall quality of the studies was poor.…”

Section: Resultsmentioning

confidence: 99%

“…The impact of EC treatment on UI was evaluated in all the studies (n = 10); the impact of EC treatment on POP was evaluated in 4 studies; and the impact of EC treatment on FI was evaluated in 3 studies (Table 1, Ref. [13][14][15][16][17][18][19][20][21][22]). Treatment of endometrial malignancies may include various combinations of surgery, external beam radiotherapy, chemotherapy, and brachytherapy based on the extent of disease and other patient characteristics.…”

Section: Resultsmentioning

confidence: 99%

“…The prevalence of PFDs was investigated in 1320 patients prior to treatment, and PFDs were evaluated in 1581 EC survivors after treatment. The mean age of the patients was 62.9 years, and the mean body mass index (BMI) was 31.8 kg/m 2 [12][13][14][15][16][17][18][19][20][21][22].…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Pelvic floor dysfunction in endometrial cancer patients after treatment. A literature review

Theodoulidis¹,

Mikos²,

Tsolakidis³

et al. 2022

Eur. J. Gynaecol. Oncol.

View full text Add to dashboard Cite

Endometrial cancer (EC) survivors are increasing progressively. However, treating this disorder may detrimentally affect the pelvic organs, resulting in pelvic floor disorders (PFD): urinary incontinence, pelvic organ prolapse, and bowel dysfunction. The aim of this review is to investigate the prevalence of PFD in EC survivors following both surgical and nonsurgical treatments. The authors conducted a structured search in the following databases: MEDLINE, EMBASE, Global Health, The Cochrane Library, and Web of Science from inception until August 2021. The inclusion criteria were: (1) women with EC, (2) observational studies, (3) original data, (4) PFD result evaluation, and (5) the use of verified tools for the evaluation of PFD. The initial search found 590 articles for PFD and endometrial cancer. Only 10 of the studies were finally available for further analysis, including 1849 individuals with EC. In total, the incidence of UI increased from 7.6% to 20.8% after EC therapy. The incidence of stress and urge UI after treatment ranged from 23 to 74.3% and 20.8 to 71.4%, respectively. The prevalence of POP was as high as 13.6% in 638 EC survivors. The prevalence of fecal incontinence was 21% in 732 EC survivors. In conclusion, PFDs are common after endometrial cancer treatment. The lack of comparative studies between the type of EC and the type of treatment limits further exploration of the differences in PFD frequency among EC survivors and the variety of EC treatments.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Pelvic floor dysfunction in endometrial cancer patients after treatment. A literature review

Theodoulidis¹,

Mikos²,

Tsolakidis³

et al. 2022

Eur. J. Gynaecol. Oncol.

View full text Add to dashboard Cite

show abstract

“…As Ziętek-Strobl and Kozłowski show in their studies, the radicality of surgery affects the patients' life. The effects have been found to depend on the range and extension of the radical operation (16,17) . Radical hysterectomy is associated with multiple complications, the most common of which is impaired bladder voiding function.…”

Section: Discussionmentioning

confidence: 98%

Nerve-sparing surgery in current gynecologic oncology

Gruszecki¹,

Pityński²

2021

Curr Gynecol Oncol

View full text Add to dashboard Cite

Nerve-sparing surgery is currently a very important topic in gynecologic oncology. In this review, it is shown that radical hysterectomy is not the only operation where the nerve-sparing technique can be used. Most surgical procedures in modern gynecologic oncology should spare the autonomic nerve structures. The review includes recently published articles precisely describing the nerve-sparing techniques in paraaortic and pelvic lymphadenectomy, and the modern approach to radical nerve-sparing hysterectomy. It has been shown in the literature that the quality of life of patients is directly dependent on the operation technique and its extension. As mentioned above, the nerve-sparing technique needs to be used not only in surgical procedures for cervical cancer, but more extensively also for endometrial and ovarian cancers. Modern techniques demonstrate that such an operation can be suitable both for the radicality and improved quality of life. Results of such operations are comparable to the old – not nerve-sparing techniques – both in terms of progression-free survival and overall survival. Nerve-sparing surgery in gynecologic oncology is our future. Better quality of life and greater patient satisfaction should be our goals. Studies are needed for better examination and comparison of the presented systematic nerve-sparing operations of lymphadenectomy in ovarian and endometrial cancers, and also combined with nerve-sparing radical hysterectomy.

show abstract

“…Likewise, the analysis that was conducted by Ziętek-Strobl et al also indicates the continuation of disorders in the urinary system after oncological treatment, which included surgery and adjuvant treatment, due to endometrial, cervical, vulval, and ovarian cancer, after six months of observation, the number of patients who reported a problem with urinary incontinence increased from 69 to 78. These authors also indicate that the risk of the problem in question occurring is not connected with the type of gynecological cancer, but rather depends on the extent of the surgery [ 42 ]. Because of this, it is indicated that reduced risk surgery should be considered in order to reduce the risk of damaging urogenital nerves and blood vessels [ 43 , 44 , 45 , 46 ].…”

Section: Discussionmentioning

confidence: 99%

Assessment of Dysfunction in the Urinary System as Well as Comfort in the Life of Women during and after Combination Therapy Due to Ovarian and Endometrial Cancer Based on the SWL, II-Q7 and UDI-6 Scales

Opławski¹,

Smoczyńska

Grabarek

et al. 2021

JCM

View full text Add to dashboard Cite

This work aimed to assess the influence of oncological combination therapy that was done on endometrial or ovarian cancer and how the urinary system is influenced as well as the quality of life in comparison to a group of female patients after the removal of the uterus with appendages due to endometrial cancer, which did not require the supplementation of therapy after operative treatment. The study included 87 patients with endometrial cancer, where, after the removal of the uterus, there was no need for conducting adjuvant therapy (C), as well as 92 female patients with endometrial cancer or 38 patients with ovarian cancer in whom combination therapy was conducted (group A, B). The assessment of the quality of life was conducted using the questionnaires: Satisfaction Life Scale (SWLS), Incontinence Impact Questionnaire, Short Form (IIQ-7), and Urogenital Distress Inventory (UDI-6) for three, six, nine, and 12 months after the conclusion of oncological treatment. It was observed that there was a statistically significant decrease in the quality of life in female patients who underwent combination therapy in comparison to a group in whose treatment only included surgery (p < 0.05). The risk of developing urinary incontinence increases alongside an increase in the scope of the operation and in the case of supplementing treatment with brachytherapy in comparison to chemotherapy.

show abstract

Urogynaecological Symptoms among Oncological Survivors and Impact of Oncological Treatment on Pelvic Floor Disorders and Lower Urinary Tract Symptoms. A Six-Month Follow-Up Study

Cited by 11 publications

References 30 publications

Pelvic floor dysfunction in endometrial cancer patients after treatment. A literature review

Pelvic floor dysfunction in endometrial cancer patients after treatment. A literature review

Nerve-sparing surgery in current gynecologic oncology

Assessment of Dysfunction in the Urinary System as Well as Comfort in the Life of Women during and after Combination Therapy Due to Ovarian and Endometrial Cancer Based on the SWL, II-Q7 and UDI-6 Scales

Contact Info

Product

Resources

About